Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma
Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma
复制标题
DOI：
10.1007/s00277-010-0945-x
复制
发表时间：
2010-09-01
影响因子：
3.5
通讯作者：
Papadopoulos, Nikolaos
中科院分区：
文献类型：
--
作者：
Chatzitolios, Anastasios;Venizelos, Ioannis;Papadopoulos, Nikolaos
凋亡相关蛋白在化疗过程中淋巴瘤细胞死亡中起重要作用。在我们的研究中，我们研究了CD 95，BCL 2和P53表达在淋巴结非霍奇金淋巴瘤（NHL）中的预后意义。我们检查了71例结节性NHL患者[45例弥漫性大B细胞淋巴瘤（DLBCL）和26例粘膜相关淋巴组织淋巴瘤（MALTL）]，35例男性和36例女性，中位年龄为65.8岁。最常见的起源部位是胃（N = 31）。石蜡包埋标本进行免疫组化分析CD 95，BCL 2和P53的表达。多因素分析显示，在DLBCL中，CD 95阳性和BCL 2阴性表达是影响总生存率的独立预后因素。对于MALTL，我们得出了相同的结论，具有阳性CD 95和阴性P53表达。在DLBCL中，CD 95阳性病例的5年总生存率为71.5%，CD 95阴性病例为35%（p = 0.004），BCL 2阴性病例的5年总生存率（70.8%）显著优于BCL 2阳性病例（37%; p = 0.009）。在MALTL中，CD 95阳性和CD 95阴性组的5年总生存率分别为89.5%和42.9%（p = 0.004），P53阳性病例的5年总生存率为50%，P53阴性病例的5年总生存率为88.9%（p = 0.016）。总之，CD 95阳性表达被证明是一个很好的预后因子的总生存在两个结节DLBCL和MALTL。相反，BCL 2和P53的阳性表达分别与结旁DLBCL和MALTL的存活率不利相关。
Apoptosis-related proteins play an important role in lymphoma cell death during chemotherapy. In our study, we investigated the prognostic significance of CD95, BCL2, and P53 expression in extranodal non-Hodgkin's lymphoma (NHL). We examined 71 patients with extranodal NHL [45 diffuse large B-cell lymphomas (DLBCLs) and 26 mucosa-associated lymphoid tissue lymphomas (MALTLs)], 35 male and 36 female, with a median age of 65.8 years. The most common site of origin was the stomach (N = 31). Paraffin-embedded specimens were analyzed immunohistochemically for CD95, BCL2, and P53 expression. Multivariate analysis revealed that in DLBCLs, positive CD95 and negative BCL2 expression were independent prognostic factors for overall survival. We reached the same conclusion for MALTLs, with positive CD95 and negative P53 expression. In DLBCLs, the 5-year overall survival rate was 71.5% for the CD95-positive cases and 35% for the CD95-negative cases (p = 0.004) and the 5-year overall survival was significantly better in BCL2-negative cases (70.8%) when compared to BCL2-positive cases (37%; p = 0.009). In MALTLs, the 5-year overall survival rate for the CD95-positive and CD95-negative groups was 89.5% and 42.9%, respectively (p = 0.004) and the 5-year overall survival rate was 50% for the P53-positive cases and 88.9% for the P53-negative cases (p = 0.016). In conclusion, positive CD95 expression proved to be a good prognostic factor of overall survival in both extranodal DLBCLs and MALTLs. In contrast, positive expression of BCL2 and P53 was found to be unfavorably associated with survival in extranodal DLBCLs and MALTLs, respectively.